StreetInsider.com News Articles

Scynexis completes Phase 1 IV study of antifungal SCY-247

Thu, 22 Oct 2026 08:01:06 -0400

Scynexis (NASDAQ: SCYX) announced topline results from its Phase 1 single and multiple ascending dose trial of the intravenous formulation of SCY-247, a triterpenoid antifungal candidate under development for the treatment and prevention of invasive fungal infections, according to a press release dated Oct. 22, 2026.

The study enrolled 56 healthy participants across seven cohorts, with 42 receiving SCY-247 by peripheral intravenous infusion and 14 receiving placebo. Single ascending doses up to 300 mg and multiple ascending doses administered once daily for seven days up to 200 mg were evaluated.

SCY-247 was reported to be generally well tolerated. The most commonly reported

SCYNEXIS Completes Phase 1 Study of Intravenous SCY-247, a Novel, Triterpenoid Antifungal in Development for Treatment and Prevention of Invasive Fungal Diseases

Thu, 22 Oct 2026 08:00:00 -0400

Intravenous SCY-247 was generally well tolerated in healthy participants, with no drug-related serious adverse events
Once-daily intravenous doses of 50 mg or higher achieved exposures at or above the target identified in murine models of invasive candidiasis
Company expects to initiate Phase 2 development of SCY-247 in oral and IV formulations in 2027, subject to regulatory agreement
SCY-247 development is advancing with the support of a BARDA contract providing up to approximately $214 million in non-dilutive funding if milestones are achieved

JERSEY CITY, N.J., Oct. 22, 2026 (GLOBE NEWSWIRE) --

SCYNEXIS Completes Phase 1 Study of Intravenous SCY-247, a Novel, Triterpenoid Antifungal in Development for Treatment and Prevention of Invasive Fungal Diseases

Thu, 22 Oct 2026 08:00:00 -0400

Intravenous SCY-247 was generally well tolerated in healthy participants, with no drug-related serious adverse events
Once-daily intravenous doses of 50 mg or higher achieved exposures at or above the target identified in murine models of invasive candidiasis
Company expects to initiate Phase 2 development of SCY-247 in oral and IV formulations in 2027, subject to regulatory agreement
SCY-247 development is advancing with the support of a BARDA contract providing up to approximately $214 million in non-dilutive funding if milestones are achieved

JERSEY CITY, N.J., Oct. 22, 2026 (GLOBE NEWSWIRE) --

SCYNEXIS to Feature SCY-247 in a Pipeline Presentation at IDWeek

Wed, 21 Oct 2026 16:05:00 -0400

JERSEY CITY, N.J., Oct. 21, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS” or the “Company”), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, announces that SCY-247, its second-generation triterpenoid (fungerp) antifungal candidate, will be featured in an oral company pipeline presentation at IDWeek, being held October 21-24, 2026 at the Walter E. Washington Convention Center in Washington, D.C. SCY-247 is under development in both oral and intravenous (IV) formulations for the treatment and prevention of invasive fungal infections with the potential to provide therapeutic advantages by having activity against drug-resistant

SCYNEXIS to Feature SCY-247 in a Pipeline Presentation at IDWeek

Wed, 21 Oct 2026 16:05:00 -0400

Scynexis reports Phase 1 results for SCY-770 kidney disease drug

Tue, 06 Oct 2026 07:30:31 -0400

Scynexis, Inc. (NASDAQ: SCYX) announced results from a Phase 1 study of SCY-770, an oral AMP-activated protein kinase (AMPK) activator being developed for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD), according to a company statement.

The study enrolled 25 healthy participants across three cohorts. The first cohort received a single 500 mg dose under fed and fasted conditions. Subsequent cohorts received either 750 mg once daily or 500 mg twice daily, or placebo, for seven days. The company said SCY-770 was well tolerated across all cohorts, with a safety profile consistent with prior clinical experience.

Scynexis said pharmacokinetic data from

SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Tue, 06 Oct 2026 07:30:00 -0400

• SCY-770 was well tolerated with a favorable safety profile in healthy adult participants at higher doses than previously evaluated

• Phase 2 proof-of-concept study in patients with ADPKD remains on-track to initiate in the fourth quarter of 2026

• SCY-770 is a potential first-in-class oral direct AMPK activator designed to address multiple underlying drivers of cyst growth and disease progression in ADPKD

JERSEY CITY, N.J., Oct. 06, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a clinical-stage biotechnology company advancing novel therapies for severe rare

SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Tue, 06 Oct 2026 07:30:00 -0400

• SCY-770 was well tolerated with a favorable safety profile in healthy adult participants at higher doses than previously evaluated

• Phase 2 proof-of-concept study in patients with ADPKD remains on-track to initiate in the fourth quarter of 2026

• SCY-770 is a potential first-in-class oral direct AMPK activator designed to address multiple underlying drivers of cyst growth and disease progression in ADPKD

JERSEY CITY, N.J., Oct. 06, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a clinical-stage biotechnology company advancing novel therapies for severe rare

Form 8-K SCYNEXIS INC For: Sep 25

Mon, 28 Sep 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260928/27114379.html

Scynexis stock surges on $214M BARDA contract for SCY-247

Mon, 28 Sep 2026 09:42:22 -0400

Investing.com -- Scynexis Inc (NASDAQ:SCYX) shares jumped 10% in premarket trading Monday after the company announced it secured a contract from the Biomedical Advanced Research and Development Authority worth up to $214 million.

The contract will fund development of SCY-247, the company's second-generation fungerp antifungal candidate designed to treat and prevent serious invasive fungal infections. The award could support the program from its current stage through New Drug Application submission for two indications if all options are exercised over a potential 10-year period.

The initial base period provides approximately $18.5 million to advance oral

Scynexis stock surges on $214M BARDA contract for SCY-247

Mon, 28 Sep 2026 09:42:22 -0400

The initial base period provides approximately $18.5 million to advance oral

Scynexis wins BARDA contract worth up to $214M for SCY-247

Mon, 28 Sep 2026 07:30:25 -0400

SCYNEXIS, Inc. (NASDAQ: SCYX) announced it has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA) to fund development of SCY-247, its second-generation antifungal candidate, according to a company statement dated Sept. 28, 2026.

The contract provides up to approximately $214 million in potential funding if all options are exercised over a period of up to 10 years. The initial base period provides approximately $18.5 million to advance oral and intravenous formulations of SCY-247 into a Phase 2 trial in patients with invasive candidiasis.

If all options are exercised, the funding would support SCY-247 development through New Drug

SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247

Mon, 28 Sep 2026 07:30:00 -0400

BARDA partnership accelerates development of SCY-247 as a potential therapy for the treatment and prevention of serious invasive fungal infections, addressing a critical public health need
Non-dilutive funding for SCY-247 enables advancement of a Phase-2 ready program, strengthening the pipeline, enhancing portfolio optionality, and bolstering the Company’s long-term value proposition
The Company does not anticipate any changes to its previously communicated guidance regarding development milestones for SCY-770, its lead product candidate for Autosomal Dominant Polycystic Kidney Disease (ADPKD), or the Company’s cash runway into 2029

JERSEY CITY, N.J., Sept. 28, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS,

SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247

Mon, 28 Sep 2026 07:30:00 -0400

BARDA partnership accelerates development of SCY-247 as a potential therapy for the treatment and prevention of serious invasive fungal infections, addressing a critical public health need
Non-dilutive funding for SCY-247 enables advancement of a Phase-2 ready program, strengthening the pipeline, enhancing portfolio optionality, and bolstering the Company’s long-term value proposition
The Company does not anticipate any changes to its previously communicated guidance regarding development milestones for SCY-770, its lead product candidate for Autosomal Dominant Polycystic Kidney Disease (ADPKD), or the Company’s cash runway into 2029

JERSEY CITY, N.J., Sept. 28, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS,

Form 4 SCYNEXIS INC For: Sep 18 Filed by: Burke Steven Keith

Tue, 22 Sep 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260922/27091005.html

Form 3 SCYNEXIS INC For: Sep 18 Filed by: Burke Steven Keith

Tue, 22 Sep 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260922/27090983.html

Form 8-K SCYNEXIS INC For: Sep 18

Tue, 22 Sep 2026 08:05:00 -0400

si-local-file:///var/storage/secattach/20260922/27088005.html

Scynexis names kidney disease drug developer Steven Burke to board

Tue, 22 Sep 2026 08:01:29 -0400

Scynexis, Inc. (NASDAQ: SCYX) announced the appointment of Steven K. Burke, M.D., to its board of directors, effective September 18, 2026.

Dr. Burke has more than 30 years of experience in drug development, with a focus on chronic kidney disease. He has served as Senior Vice President, Chief Research and Development Officer and Chief Medical Officer at Akebia Therapeutics, Inc. since 2021, where he has had a leadership role in the development of Vafseo® (vadadustat) for anemia due to chronic kidney disease. Prior to Akebia, he founded Abfero Pharmaceuticals, Inc., which was later acquired by Pharmacosmos A/S, and served as Senior

SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors

Tue, 22 Sep 2026 08:00:00 -0400

JERSEY CITY, N.J., Sept. 22, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS” or the “Company”), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced the appointment of Steven K. Burke, M.D., to its Board of Directors, effective September 18, 2026.

Dr. Burke brings more than 30 years of industry experience, with a particular focus on drug development for chronic kidney disease. He has worked at Akebia Therapeutics, Inc. since 2019, and has served as its Senior Vice President, Chief Research and Development Officer and Chief Medical Officer

SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors

Tue, 22 Sep 2026 08:00:00 -0400

Scynexis names Todd Minga as SVP of Research & Development

Tue, 15 Sep 2026 08:01:34 -0400

Scynexis, Inc. (NASDAQ: SCYX) has appointed Todd Minga, M.D., as Senior Vice President, Research & Development, effective September 14, 2026, according to a company statement.

Dr. Minga joins Scynexis from Akebia Therapeutics, where he served as Vice President, Medical Affairs and Clinical Development. He previously held positions at Maze Therapeutics and IQVIA, and practiced as a board-certified nephrologist for more than 16 years.

David Angulo, M.D., Chief Executive Officer of Scynexis, cited Dr. Minga's background in kidney disease and drug development as relevant to the company's pipeline, which includes SCY-770, a candidate being developed for autosomal dominant polycystic kidney disease, and SCY-247,

SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development

Tue, 15 Sep 2026 08:00:00 -0400

JERSEY CITY, N.J., Sept. 15, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (the Company or SCYNEXIS), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced the appointment of Todd Minga, M.D. as Senior Vice President, Research & Development, effective September 14, 2026.

Dr. Minga brings more than two decades of experience spanning clinical medicine, drug development, medical affairs, clinical research, and strategic leadership in kidney disease and rare disorders. He joins SCYNEXIS from Akebia Therapeutics, where he most recently served as Vice President, Medical Affairs and Clinical Development.

SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development

Tue, 15 Sep 2026 08:00:00 -0400

Form 4 SCYNEXIS INC For: Sep 09 Filed by: Subramanian Sanjay

Fri, 11 Sep 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260911/27052812.html

Form 3 SCYNEXIS INC For: Sep 09 Filed by: Subramanian Sanjay

Fri, 11 Sep 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260911/27052789.html